Clinics and research in hepatology and gastroenterology最新文献

{"title":"Involvement of oxidative stress, lipid dysmetabolism and gut microbiol dysbiosis in oxaliplatin-induced fatty liver disease: evidence from a tree shrew model","authors":"Yulei Lu ,&nbsp;Fei Yi ,&nbsp;Wende Chen ,&nbsp;Xinglong Tan ,&nbsp;Kezhi Li ,&nbsp;Chun Yang ,&nbsp;Youzhi Lin","doi":"10.1016/j.clinre.2025.102645","DOIUrl":"10.1016/j.clinre.2025.102645","url":null,"abstract":"<div><h3>Background</h3><div>Oxaliplatin is cornerstone treatment for colorectal cancer, yet a significant proportion of patients develop drug-induced fatty liver disease (DILI). How it induces such liver injury is poorly understood and whether the gut microbiome is involved remains unknown.</div></div><div><h3>Methods</h3><div>A male tree shrew model of oxaliplatin-induced DILI was established by six intraperitoneal injections (7 mg/kg every two weeks). During the early and late phases of liver injury, liver tissue was analyzed in terms of histopathology, oxidative stress and transcriptional profiling, while feces were subjected to microbial profiling based on 16S rRNA sequencing.</div></div><div><h3>Results</h3><div>The model recapitulated key features of DILI, including severe hepatocyte steatosis and ballooning in the early phase after the final treatment, mild hepatic steatosis with sinusoidal dilatation in the late phase, and persistent hepatic oxidative stress during both phases. Transcriptional analysis of liver tissue identified 1503 differentially expressed genes (DEGs) between oxaliplatin-treated and control animals, of which 601 DEGs differed between treated animals in the early or late phases after the final treatment of DILI. Pathway enrichment revealed significant dysregulation in oxidative stress (e.g. NDUFA12, OSR1, MPO) and lipid metabolism (e.g., LDAH, ACACB, CH25H, LIPE) genes. Gut microbiota profiling showed an increase in the relative abundance of potentially harmful bacteria (e.g., <em>Parabacteroides, Rikenella, Alistipes</em> and <em>Faecalitalea)</em> and a concurrent decrease in the abundance of anti-oxidative bacteria (e.g., <em>Lactococcus</em> and <em>Flavobacterium)</em>. Notably, abundance of several microbial genera in the gut correlated with liver expression of genes involved in oxidative stress and lipid metabolism as well as with levels of oxidative stress markers, and/or fat deposition in the liver.</div></div><div><h3>Conclusion</h3><div>Our results suggest that our tree shrew model can faithfully replicate key characteristics of oxaliplatin-induced fatty liver disease, and that such disease involves oxidative stress and lipid dysmetabolism in the liver as well as dysbiosis of microbiota in the gut.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102645"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A call for increased advocacy and universal resources to support effective nutritional interventions in the comprehensive management of patients with cirrhosis","authors":"Cristal Brown","doi":"10.1016/j.clinre.2025.102650","DOIUrl":"10.1016/j.clinre.2025.102650","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102650"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S. adult population","authors":"Ayesha Sualeheen ,&nbsp;Sze-Yen Tan ,&nbsp;Robin M. Daly ,&nbsp;Ekavi Georgousopoulou ,&nbsp;Gavin Abbott ,&nbsp;Stuart K. Roberts ,&nbsp;Jacob George ,&nbsp;Elena S. George","doi":"10.1016/j.clinre.2025.102649","DOIUrl":"10.1016/j.clinre.2025.102649","url":null,"abstract":"<div><h3>Introduction</h3><div>Metabolic dysfunction associated steatotic liver disease (MASLD) has replaced NAFLD as the diagnostic standard. This study aimed to validate non-invasive tests (NITs) for hepatic steatosis and fibrosis, originally used for NAFLD, in predicting MASLD and advanced fibrosis, respectively, compared to transient elastography (TE).</div></div><div><h3>Methods</h3><div>This cross-sectional study used the NHANES database (2017–2020). Adults aged ≥18 years with valid TE status and without other steatotic liver diseases were included. Hepatic steatosis NITs were compared against controlled attenuation parameter (CAP)- diagnosed MASLD and fibrosis NITS were compared against liver stiffness measurement (LSM)-diagnosed advanced fibrosis. The diagnostic accuracy was assessed using weighted ROC analysis.</div></div><div><h3>Results</h3><div>Among 5305 participants (49.1 % males), MASLD prevalence was 42.8 % (CAP-diagnosed) and advanced fibrosis was identified in 10.4 % (LSM-diagnosed) in those with MASLD. Steatosis NITs showed good diagnostic accuracy for predicting MASLD (AUROC 0.836 to 0.862), with fatty liver index having the maximum Youden index (0.55). Fibrosis NITs indicated poor to fair diagnostic accuracy for predicting advanced fibrosis (AUROC 0.564 to 0.691) but indicated high negative predicted value (89 %-94 %). In age categorized subgroup analysis, fibrosis NITs performed poorly in those aged ≤ 35 years and had low specificity to exclude fibrosis in those aged ≥65 years but performed comparably to the overall MASLD cohort in those aged 36–64 years.</div></div><div><h3>Conclusion</h3><div>In this population-based cohort of U.S. adults, all steatosis NITs demonstrated good diagnostic accuracy for MASLD. However, the fibrosis NITs showed limited diagnostic ability and were influenced by age, suggesting they should be used cautiously in general population.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102649"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biopsy of a hepatic small vessel neoplasm: beware of bleeding","authors":"Claire Michoud ,&nbsp;Valérie Hervieu ,&nbsp;Hélène Gimonet ,&nbsp;Jérôme Dumortier","doi":"10.1016/j.clinre.2025.102644","DOIUrl":"10.1016/j.clinre.2025.102644","url":null,"abstract":"","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102644"},"PeriodicalIF":2.6,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends, disparities, and outcomes of drug-induced pancreatitis in the United States: A nationwide analysis (2016–2020)","authors":"Guy Loic Nguefang Tchoukeu ,&nbsp;Sarpong Boateng ,&nbsp;Joel Gabin Konlack Mekontso ,&nbsp;Yazan A Al-Ajlouni ,&nbsp;Basile Njei","doi":"10.1016/j.clinre.2025.102641","DOIUrl":"10.1016/j.clinre.2025.102641","url":null,"abstract":"<div><h3>Background</h3><div>Drug-induced pancreatitis (DIP) is an underreported etiology of acute pancreatitis. DIP risk and prevalence has increased over the years with polypharmacy. Data on affected patients in the U.S. remain limited. We aim to assess disparities and outcomes in DIP hospitalizations.</div></div><div><h3>Methods</h3><div>Retrospective study including adults diagnosed with DIP using the National Inpatient Sample (NIS) database (2016–2020). The primary outcomes were inpatient mortality, and complications. Secondary outcomes included resource utilization metrics. Descriptive statistics, linear regression, and logistic regression were performed using SAS 9.4.</div></div><div><h3>Results</h3><div>5666 patients (mean age: 56.5 years; females 53.6 %) were included. Common comorbidities were hypertension (61.3 %), hyperlipidemia (42.3 %), and diabetes (22.9 %). The mortality rate was 1.5 %, with acute kidney injury (20.6 %), Sepsis (5.0 %), ileus (3.5 %) the common complications. The Mean LOS was 5.5 days, and the mean hospital charges were $60,811.20. Compared to White, Hispanics had significant odds of DIP admission (aOR: 1.11, 95 % CI: 1.01–1.21, <em>p</em> = 0.03) and increased risk of cardiac arrest (aOR 4.34, 95 % CI 1.17–15.35, <em>p</em> = 0.02). Black patients had significantly higher odds of severe DIP (aOR 1.26, 95 % CI 1.02–1.56, <em>p</em> = 0.03) and acute kidney injury (aOR 1.29, 95 % CI 1.04–1.61, <em>p</em> = 0.02), while Asian were more likely to develop sepsis (aOR 2.10, 95 % CI 1.07–3.83, <em>p</em> = 0.02), had higher hospital charges (+$42,008, <em>p</em> = 0.039) and longer LOS (+2.5 days, <em>p</em> &lt; 0.01)..</div></div><div><h3>Conclusion</h3><div>There are significant racial disparities among patients and a substantial economic burden on healthcare systems. Multifaceted strategies and research into genetic and socioeconomic predispositions are needed to address DIP.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102641"},"PeriodicalIF":2.6,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver fibrosis evaluation in patients with psychiatric diseases","authors":"Paul Carrier ,&nbsp;Morgane Chalange ,&nbsp;Murielle Girard ,&nbsp;Aurélie Prémaud ,&nbsp;Mireille Okassa ,&nbsp;Aurélie Lacroix ,&nbsp;Marilyne Debette-Gratien ,&nbsp;Brigitte Plansont ,&nbsp;Alexandre Buisson ,&nbsp;Benjamin Calvet ,&nbsp;Céline Rigaud ,&nbsp;Jérôme Boursier ,&nbsp;Philippe Nubukpo ,&nbsp;Véronique Loustaud-Ratti","doi":"10.1016/j.clinre.2025.102636","DOIUrl":"10.1016/j.clinre.2025.102636","url":null,"abstract":"<div><div>Introduction: Mental illnesses and psychiatric disorders are public health problems, with an increasing prevalence. Life expectancy of patients is compromised by comorbid somatic illnesses, including liver diseases. Screening for liver fibrosis in this population is challenging.</div><div>Materials &amp; Methods: We assessed liver fibrosis using liver stiffness (LS) measurement by FibroScan® in a large cohort of patients with severe psychiatric disorders receiving psychotropic medications for at least two years. Liver steatosis was evaluated using the Controlled Attenuation Parameter™ (CAP).</div><div>Results: 355 patients were prospectively included. Advanced fibrosis (LS &gt;8 kPa) prevalence was 6 %. In univariate analysis, advanced fibrosis was associated with high blood pressure (<em>p</em> &lt; 0.001), high ferritin concentration (<em>p</em> = 0.028), and psychotropic drug exposure (<em>p</em> = 0.036). In multivariate analysis, high blood pressure only remained significant (<em>p</em> = 0.002). 34.9 % of patients had significant steatosis (CAP &gt;275 dB/m). In univariate analysis, steatosis was associated with sleep apnea syndrome (<em>p</em> = 0.016), past alcohol dependence (<em>p</em> = 0.013), high body mass index (BMI), type 2 diabetes (<em>p</em> = 0.003), elevated triglycerides (<em>p</em> &lt; 0.001), metabolic syndrome (<em>p</em> &lt; 0.001), metabolic dysfunction-associated liver disease (<em>p</em> &lt; 0.001), and high ferritin concentration (<em>p</em> = 0.008). In multivariable analysis, high BMI and elevated triglycerides remained significant.</div><div>Conclusion: Psychiatric patients are at risk of liver fibrosis and steatosis. Systematic screening for liver diseases should be required. Further studies are needed to determine the best strategies for prevention and treatment.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102636"},"PeriodicalIF":2.6,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anorectal physiotherapy in coloproctology: Guidelines of the french national society of coloproctology","authors":"Damien Soudan ,&nbsp;Amine Alam ,&nbsp;Gwendoline Basile ,&nbsp;Christine Bataillon ,&nbsp;Sylvie Billecocq ,&nbsp;Najima Bouta ,&nbsp;Charlène Brochard ,&nbsp;Charlotte Desprez ,&nbsp;Jean-Luc Faucheron ,&nbsp;Anne-Marie Leroi ,&nbsp;Martine Loobuyck ,&nbsp;Diane Mege ,&nbsp;Pauline Roumeguere ,&nbsp;Aurélien Venara ,&nbsp;Véronique Vitton","doi":"10.1016/j.clinre.2025.102637","DOIUrl":"10.1016/j.clinre.2025.102637","url":null,"abstract":"<div><div>Anorectal physiotherapy is a safe, effective, and commonly prescribed treatment for a wide range of functional anorectal disorders. It is usually integrated into a broader medical and surgical treatment plan. For optimal outcomes, sessions must be delivered by experienced practitioners and require active patient motivation. However, access to such expertise remains limited due to a shortage of trained professionals. A clear understanding of appropriate indications and physiotherapy modalities is essential for effective patient care coordination. Currently, no national guidelines are available in France. Therefore, the French National Society of Coloproctology (SNFCP) has developed clinical practice guidelines for the use of anorectal physiotherapy in coloproctology. A panel of 15 French experts in coloproctology conducted a systematic literature review and developed graded recommendations according to HAS guidelines. When data were lacking, expert agreements were established through a voting process.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102637"},"PeriodicalIF":2.6,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic factors drive early increase in hepatic steatosis despite improvement in non-invasive fibrosis markers after hepatitis C eradication with direct-acting antivirals","authors":"Mohamed Shengir ,&nbsp;Wesal Elgretli ,&nbsp;Felice Cinque ,&nbsp;Agnihotram V. Ramanakumar ,&nbsp;Rosa Lombardi ,&nbsp;Annalisa Cespiati ,&nbsp;Anna Ludovica Fracanzani ,&nbsp;Luz Ballesteros ,&nbsp;Marc Deschenes ,&nbsp;Philip Wong ,&nbsp;Tianyan Chen ,&nbsp;Giada Sebastiani","doi":"10.1016/j.clinre.2025.102639","DOIUrl":"10.1016/j.clinre.2025.102639","url":null,"abstract":"<div><h3>Background</h3><div>While direct-acting antivirals (DAAs) achieve high sustained virologic response (SVR) rates in people with hepatitis C virus (HCV), their impact on hepatic steatosis (HS) remains unclear.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of 108 HCV patients from McGill University and the University of Milan who achieved SVR following DAAs. Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were used to assess HS and liver fibrosis at baseline and 24 weeks post-SVR. HS was defined as CAP ≥248 dB/m, significant liver fibrosis as LSM ≥8 kPa, and metabolic dysfunction-associated steatotic liver disease (MASLD) as HS plus ≥1 cardiometabolic risk factors. Changes were evaluated using Wilcoxon signed-rank test and standardized mean difference (SMD). Multivariable logistic regression identified predictors of post-SVR HS.</div></div><div><h3>Results</h3><div>HS prevalence increased from 47 % to 61 % post-SVR (<em>p</em> = 0.0007, SMD = 0.30). Among patients with baseline HS, 88 % had persistent steatosis. New-onset steatosis developed in 37 % of patients without baseline HS, with a significant CAP increase (<em>p</em> &lt; 0.0004, SMD=0.48). In patients without baseline HS, total cholesterol and triglycerides increased (<em>p</em> = 0.0084, SDM = 0.43 and <em>p</em> &lt; 0.0001, SDM = 0.71, respectively), whereas in those with baseline HS, only total cholesterol rose (<em>p</em> = 0.0296, SDM = 0.50). MASLD remained the leading etiology at both time points (94 % at baseline, 92 % post-SVR). Significant fibrosis declined markedly from 49 % to 17 % (<em>p</em> &lt; 0.0001, SMD = –0.80). Higher BMI at 24 weeks was independently associated with HS (adjusted odds ratio 1.92, 95 %CI 1.22–3.03).</div></div><div><h3>Conclusions</h3><div>Despite improvement in liver fibrosis markers, HS often persists or emerges following DAAs therapy, particularly alongside metabolic dysfunctions marked by elevated cholesterol and triglycerides.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102639"},"PeriodicalIF":2.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144312718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unrevealing emphysematous gastritis: Insight from a comprehensive systematic review","authors":"Mohamed Elnaggar ,&nbsp;Omar F Abbas ,&nbsp;Roaa Haddad ,&nbsp;Mohamed Mohsen Helal ,&nbsp;Hala AbouShawareb ,&nbsp;Alaa Abdrabou Abouelmagd ,&nbsp;Abdullah Almarfadi ,&nbsp;Ahmed Galal Amer ,&nbsp;Yousif Ahmad Hanafi Hussein ,&nbsp;Motasem Ayoub ,&nbsp;Mohamed Ayman Ebrahim ,&nbsp;Mohamed A. Aldemerdash ,&nbsp;Ismail Elkhattib ,&nbsp;Mohamed Ghallab ,&nbsp;Hatem Eltaly ,&nbsp;Mohamed Abd El Aziz ,&nbsp;Neil Parikh","doi":"10.1016/j.clinre.2025.102638","DOIUrl":"10.1016/j.clinre.2025.102638","url":null,"abstract":"<div><h3>Background</h3><div>Emphysematous Gastritis is a rare condition, characterized by the presence of gas within the gastric wall. It is associated with a high mortality rate, but early diagnosis and treatment can significantly reduce mortality and improve patient outcomes.</div></div><div><h3>Methodology</h3><div>For this systematic review, we searched PubMed, Scopus, Web of Science, and Embase from inception until October 2024 to find relevant case reports or case series on emphysematous gastritis.</div></div><div><h3>Results</h3><div>A 116 case report and case series revealed that patient ages ranged from 4 months to 96 years (mean age: 55), male (55 %). Most cases were reported in Asia and the USA. The majority of symptoms were 90 % abdominal pain, and 80 % vomiting and nausea. Infection of the gastric wall by gas-forming organisms was commonly Sarcina ventriculi. Abdominal CT scans identified emphysematous changes in 95 % of cases. Endoscopic examinations revealed Gastric Mucosal Erythema in 80 % of patients, with elevated leukocytosis in 80 % of cases. The majority of the recovery rate was 70 %, and the mortality rate was 15 %; (75 % received medical treatment,25 % surgical treatment), and 79 % were given medical treatment including antibiotics and supportive care while in severe cases 21 % were surgical.</div></div><div><h3>Conclusion</h3><div>Emphysematous Gastritis requires a multidisciplinary approach for optimal outcomes. CT imaging remains pivotal for diagnosis, and management should be individualized based on disease severity and patient factors. While mortality remains significant, early recognition and advancements in medical care have improved survival in many cases.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102638"},"PeriodicalIF":2.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the benefit of optimal MASH treatment depend on a reduction in myosteatosis?","authors":"Nicolas Lanthier","doi":"10.1016/j.clinre.2025.102640","DOIUrl":"10.1016/j.clinre.2025.102640","url":null,"abstract":"<div><div>The muscle-liver axis, well known in cirrhosis, is also important in the multisystem disease known as metabolic dysfunction-associated steatohepatitis (MASH). The convincing results obtained with a triple peroxisome proliferator-activated receptor (PPAR) agonist in this setting confirm this hypothesis, demonstrating a beneficial effect not only on the severity of MASH in terms of steatosis, inflammation and fibrosis, but also in terms of hepatic and muscle insulin sensitivity. The pathophysiology of MASH and mechanism of action of triple PPAR agonist suggest that this may be related to improved lipid management in skeletal muscles and highlights the importance of studying the muscle-adipose tissue-liver axis in the management of MASH.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102640"},"PeriodicalIF":2.6,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}